<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34424963</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1528-0020</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>139</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>Blood</Title>
          <ISOAbbreviation>Blood</ISOAbbreviation>
        </Journal>
        <ArticleTitle>T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome.</ArticleTitle>
        <Pagination>
          <StartPage>369</StartPage>
          <EndPage>383</EndPage>
          <MedlinePgn>369-383</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1182/blood.2021012924</ELocationID>
        <Abstract>
          <AbstractText>Pediatric Evans syndrome (pES) is increasingly identified as the presenting manifestation of several inborn errors of immunity. Despite an improved understanding of genetic defects in pES, the underlying immunobiology of pES is poorly defined, and characteristic diagnostic immune parameters are lacking. We describe the immune characteristics of 24 patients with pES and compared them with 22 patients with chronic immune thrombocytopenia (cITP) and 24 healthy controls (HCs). Compared with patients with cITP and HC, patients with pES had increased circulating T-follicular helper cells (cTfh), increased T-cell activation, and decreased naïve CD4+ T cells for age. Despite normal or high immunoglobulin G (IgG) in most pES at presentation, class-switched memory B cells were decreased. Within the cTfh subset, we noted features of postactivation exhaustion with upregulation of several canonical checkpoint inhibitors. T-cell receptor β chain (TCR-β) repertoire analysis of cTfh cells revealed increased oligoclonality in patients with pES compared with HCs. Among patients with pES, those without a known gene defect had a similar characteristic immune abnormality as patients with defined genetic defects. Similarly, patients with pES with normal IgG had similar T-cell abnormalities as patients with low IgG. Because genetic defects have been identified in less than half of patients with pES, our findings of similar immune abnormalities across all patients with pES help establish a common characteristic immunopathology in pES, irrespective of the underlying genetic etiology.</AbstractText>
          <CopyrightInformation>© 2022 by The American Society of Hematology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kumar</LastName>
            <ForeName>Deepak</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Aflac Cancer and Blood Disorder Center, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Prince</LastName>
            <ForeName>Chengyu</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Aflac Cancer and Blood Disorder Center, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bennett</LastName>
            <ForeName>Carolyn M</ForeName>
            <Initials>CM</Initials>
            <AffiliationInfo>
              <Affiliation>Aflac Cancer and Blood Disorder Center, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Briones</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Aflac Cancer and Blood Disorder Center, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lucas</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Aflac Cancer and Blood Disorder Center, Children's Healthcare of Atlanta, Atlanta; GA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Russell</LastName>
            <ForeName>Athena</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-5478-921X</Identifier>
            <AffiliationInfo>
              <Affiliation>Genetics and Molecular Biology Graduate Program, Laney Graduate School, Emory University, Atlanta, GA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Kiran</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Allergy/Immunology Section, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chonat</LastName>
            <ForeName>Satheesh</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-5909-0800</Identifier>
            <AffiliationInfo>
              <Affiliation>Aflac Cancer and Blood Disorder Center, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Graciaa</LastName>
            <ForeName>Sara</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Aflac Cancer and Blood Disorder Center, Children's Healthcare of Atlanta, Atlanta; GA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Edington</LastName>
            <ForeName>Holly</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0001-7315-5917</Identifier>
            <AffiliationInfo>
              <Affiliation>Aflac Cancer and Blood Disorder Center, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>White</LastName>
            <ForeName>Michael H</ForeName>
            <Initials>MH</Initials>
            <Identifier Source="ORCID">0000-0002-8638-8741</Identifier>
            <AffiliationInfo>
              <Affiliation>Aflac Cancer and Blood Disorder Center, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kobrynski</LastName>
            <ForeName>Lisa</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Allergy/Immunology Section, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abdalgani</LastName>
            <ForeName>Manar</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Children's Minnesota, Minneapolis, MN.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Parikh</LastName>
            <ForeName>Suhag</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-6066-9852</Identifier>
            <AffiliationInfo>
              <Affiliation>Aflac Cancer and Blood Disorder Center, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chandra</LastName>
            <ForeName>Sharat</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-2933-814X</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Bone Marrow Transplantation and Immune Deficiency, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bleesing</LastName>
            <ForeName>Jack</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Bone Marrow Transplantation and Immune Deficiency, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marsh</LastName>
            <ForeName>Rebecca</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Bone Marrow Transplantation and Immune Deficiency, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Sunita</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Children's Healthcare of Atlanta, Atlanta, GA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Waller</LastName>
            <ForeName>Edmund K</ForeName>
            <Initials>EK</Initials>
            <Identifier Source="ORCID">0000-0003-0816-6729</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA; and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Prahalad</LastName>
            <ForeName>Sampath</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-3489-1756</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Pediatric Rheumatology, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chandrakasan</LastName>
            <ForeName>Shanmuganathan</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-8007-9932</Identifier>
            <AffiliationInfo>
              <Affiliation>Aflac Cancer and Blood Disorder Center, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K08 HL141635</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>K12 HD072245</GrantID>
            <Acronym>HD</Acronym>
            <Agency>NICHD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U54 AI082973</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Blood</MedlineTA>
        <NlmUniqueID>7603509</NlmUniqueID>
        <ISSNLinking>0006-4971</ISSNLinking>
      </MedlineJournalInfo>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C536380">Evans Syndrome</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Blood. 2022 Jan 20;139(3):312-313</RefSource>
          <PMID Version="1">35050333</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000744" MajorTopicYN="N">Anemia, Hemolytic, Autoimmune</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008213" MajorTopicYN="Y">Lymphocyte Activation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016553" MajorTopicYN="N">Purpura, Thrombocytopenic, Idiopathic</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006377" MajorTopicYN="N">T-Lymphocytes, Helper-Inducer</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013921" MajorTopicYN="N">Thrombocytopenia</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>23</Day>
          <Hour>17</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34424963</ArticleId>
        <ArticleId IdType="pmc">PMC8777200</ArticleId>
        <ArticleId IdType="doi">10.1182/blood.2021012924</ArticleId>
        <ArticleId IdType="pii">S0006-4971(21)01512-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Evans RS, Takahashi K, Duane RT, Payne R, Liu C. Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch Intern Med.
1951;87(1):48-65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14782741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teachey DT, Lambert MP. Diagnosis and management of autoimmune cytopenias in childhood. Pediatr Clin North Am.
2013;60(6):1489-1511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5384653</ArticleId>
            <ArticleId IdType="pubmed">24237984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michel M, Chanet V, Dechartres A, et al. . The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood.
2009;114(15):3167-3172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19638626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miano M. How I manage Evans Syndrome and AIHA cases in children. Br J Haematol.
2016;172(4):524-534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26625877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savaşan S, Warrier I, Ravindranath Y. The spectrum of Evans’ syndrome. Arch Dis Child.
1997;77(3):245-248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1717303</ArticleId>
            <ArticleId IdType="pubmed">9370906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seidel MG. Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Blood.
2014;124(15):2337-2344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4192747</ArticleId>
            <ArticleId IdType="pubmed">25163701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Notarangelo LD, Uzel G, Rao VK. Primary immunodeficiencies: novel genes and unusual presentations. Hematology (Am Soc Hematol Educ Program).
2019;2019(1):443-448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6913429</ArticleId>
            <ArticleId IdType="pubmed">31808899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seidel MG. Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs). Hematology (Am Soc Hematol Educ Program).
2020;2020(1):673-679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7727533</ArticleId>
            <ArticleId IdType="pubmed">33275670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aladjidi N, Fernandes H, Leblanc T, et al. . Evans syndrome in children: long-term outcome in a prospective French national observational cohort. Front Pediatr.
2015;3:79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4586429</ArticleId>
            <ArticleId IdType="pubmed">26484337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rivalta B, Zama D, Pancaldi G, et al. . Evans syndrome in childhood: long term follow-up and the evolution in primary immunodeficiency or rheumatological disease. Front Pediatr.
2019;7:304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6664023</ArticleId>
            <ArticleId IdType="pubmed">31396497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cifaldi C, Brigida I, Barzaghi F, et al. . Targeted NGS platforms for genetic screening and gene discovery in primary immunodeficiencies. Front Immunol.
2019;10:316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6470723</ArticleId>
            <ArticleId IdType="pubmed">31031743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amaya-Uribe L, Rojas M, Azizi G, Anaya JM, Gershwin ME. Primary immunodeficiency and autoimmunity: A comprehensive review. J Autoimmun.
2019;99:52-72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30795880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tavakol M, Jamee M, Azizi G, et al. . Diagnostic approach to the patients with suspected primary immunodeficiency. Endocr Metab Immune Disord Drug Targets.
2020;20(2):157-171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31456526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rudilla F, Franco-Jarava C, Martínez-Gallo M, et al. . Expanding the clinical and genetic spectra of primary immunodeficiency-related disorders with clinical exome sequencing: expected and unexpected findings. Front Immunol.
2019;10:2325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6797824</ArticleId>
            <ArticleId IdType="pubmed">31681265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadjadj J, Aladjidi N, Fernandes H, et al. ; members of the French Reference Center for Pediatric Autoimmune Cytopenia (CEREVANCE) . Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. Blood.
2019;134(1):9-21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30940614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molnár E, Radwan N, Kovács G, et al. . Key diagnostic markers for autoimmune lymphoproliferative syndrome with molecular genetic diagnosis. Blood.
2020;136(17):1933-1945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32599613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveira JB, Bleesing JJ, Dianzani U, et al. . Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood.
2010;116(14):e35-e40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2953894</ArticleId>
            <ArticleId IdType="pubmed">20538792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, et al. . FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood.
2009;113(13):3027-3030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19176318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aringer M, Costenbader K, Daikh D, et al. . 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol.
2019;71(9):1400-1412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6827566</ArticleId>
            <ArticleId IdType="pubmed">31385462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linderman GC, Rachh M, Hoskins JG, Steinerberger S, Kluger Y. Fast interpolation-based t-SNE for improved visualization of single-cell RNA-seq data. Nat Methods.
2019;16(3):243-245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6402590</ArticleId>
            <ArticleId IdType="pubmed">30742040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gensous N, Charrier M, Duluc D, et al. . T follicular helper cells in autoimmune disorders. Front Immunol.
2018;9:1637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6056609</ArticleId>
            <ArticleId IdType="pubmed">30065726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson N, Gatenby PA, Wilson A, et al. . Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum.
2010;62(1):234-244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20039395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viisanen T, Ihantola EL, Näntö-Salonen K, et al. . Circulating CXCR5+PD-1+ICOS+ follicular T helper cells are increased close to the diagnosis of type 1 diabetes in children with multiple autoantibodies. Diabetes.
2017;66(2):437-447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28108610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Lindwall E, Gauthier C, et al. . Circulating CXCR5+CD4+helper T cells in systemic lupus erythematosus patients share phenotypic properties with germinal center follicular helper T cells and promote antibody production. Lupus.
2015;24(9):909-917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25654980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schubert D, Bode C, Kenefeck R, et al. . Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med.
2014;20(12):1410-1416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4668597</ArticleId>
            <ArticleId IdType="pubmed">25329329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucas CL, Kuehn HS, Zhao F, et al. . Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol.
2014;15(1):88-97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4209962</ArticleId>
            <ArticleId IdType="pubmed">24165795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuehn HS, Ouyang W, Lo B, et al. . Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science.
2014;345(6204):1623-1627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4371526</ArticleId>
            <ArticleId IdType="pubmed">25213377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa-Carvalho BT, de Moraes-Pinto MI, de Almeida LC, et al. . A remarkable depletion of both naïve CD4+ and CD8+ with high proportion of memory T cells in an IPEX infant with a FOXP3 mutation in the forkhead domain. Scand J Immunol.
2008;68(1):85-91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18489537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bateman EA, Ayers L, Sadler R, et al. . T cell phenotypes in patients with common variable immunodeficiency disorders: associations with clinical phenotypes in comparison with other groups with recurrent infections. Clin Exp Immunol.
2012;170(2):202-211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3482367</ArticleId>
            <ArticleId IdType="pubmed">23039891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nurieva RI, Chung Y, Martinez GJ, et al. . Bcl6 mediates the development of T follicular helper cells. Science.
2009;325(5943):1001-1005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2857334</ArticleId>
            <ArticleId IdType="pubmed">19628815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnston RJ, Poholek AC, DiToro D, et al. . Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science.
2009;325(5943):1006-1010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2766560</ArticleId>
            <ArticleId IdType="pubmed">19608860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuchen S, Robbins R, Sims GP, et al. . Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J Immunol.
2007;179(9):5886-5896.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17947662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA. Inflammasome activation and IL-1β and IL-18 processing during infection. Trends Immunol.
2011;32(3):110-116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21333600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss ES, Girard-Guyonvarc’h C, Holzinger D, et al. . Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood.
2018;131(13):1442-1455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5877443</ArticleId>
            <ArticleId IdType="pubmed">29326099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzucchelli R, Hixon JA, Spolski R, et al. . Development of regulatory T cells requires IL-7Ralpha stimulation by IL-7 or TSLP. Blood.
2008;112(8):3283-3292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2569178</ArticleId>
            <ArticleId IdType="pubmed">18664628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romberg N, Le Coz C, Glauzy S, et al. . Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses. J Allergy Clin Immunol.
2019;143(1):258-265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6400323</ArticleId>
            <ArticleId IdType="pubmed">29935219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Chen Z, Wang H, et al. . Follicular regulatory T cells: a novel target for immunotherapy?
Clin Transl Immunology.
2020;9(2):e1106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7019198</ArticleId>
            <ArticleId IdType="pubmed">32082569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alroqi FJ, Charbonnier LM, Baris S, et al. . Exaggerated follicular helper T-cell responses in patients with LRBA deficiency caused by failure of CTLA4-mediated regulation. J Allergy Clin Immunol.
2018;141(3):1050-1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5743769</ArticleId>
            <ArticleId IdType="pubmed">28601686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer.
2019;18(1):155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6833286</ArticleId>
            <ArticleId IdType="pubmed">31690319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Coz C, Bengsch B, Khanna C, et al. . Common variable immunodeficiency-associated endotoxemia promotes early commitment to the T follicular lineage. J Allergy Clin Immunol.
2019;144(6):1660-1673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6900457</ArticleId>
            <ArticleId IdType="pubmed">31445098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vinuesa CG, Cook MC, Angelucci C, et al. . A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature.
2005;435(7041):452-458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15917799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linterman MA, Rigby RJ, Wong RK, et al. . Follicular helper T cells are required for systemic autoimmunity. J Exp Med.
2009;206(3):561-576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2699132</ArticleId>
            <ArticleId IdType="pubmed">19221396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Yu M, Zheng Y, et al. . CXCR5+PD-1+ follicular helper CD8 T cells control B cell tolerance. Nat Commun.
2019;10(1):4415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6765049</ArticleId>
            <ArticleId IdType="pubmed">31562329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity.
2014;41(4):529-542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4223692</ArticleId>
            <ArticleId IdType="pubmed">25367570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan O, Giles JR, McDonald S, et al. . TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature.
2019;571(7764):211-218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6713202</ArticleId>
            <ArticleId IdType="pubmed">31207603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bordon Y. TOX for tired T cells. Nat Rev Immunol.
2019;19(8):476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31243349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Page N, Klimek B, De Roo M, et al. . Expression of the DNA-binding factor TOX promotes the encephalitogenic potential of microbe-induced autoreactive CD8+ T cells [correction published in Immunity. 2019;50(3):P763]. Immunity.
2018;48(5):937-950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6040915</ArticleId>
            <ArticleId IdType="pubmed">29768177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bride KL, Vincent T, Smith-Whitley K, et al. . Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood.
2016;127(1):17-28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4705607</ArticleId>
            <ArticleId IdType="pubmed">26504182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rokaw MD, West M, Johnson JP. Rapamycin inhibits protein kinase C activity and stimulates Na+ transport in A6 cells. J Biol Chem.
1996;271(50):32468-32473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8943313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin-Perez M, Grillo AS, Ito TK, et al. . PKC downregulation upon rapamycin treatment attenuates mitochondrial disease. Nat Metab.
2020;2(12):1472-1481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8017771</ArticleId>
            <ArticleId IdType="pubmed">33324011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jasinski S, Weinblatt ME, Glasser CL. Sirolimus as an effective agent in the treatment of immune thrombocytopenia (ITP) and Evans syndrome (ES): a single institution’s experience. J Pediatr Hematol Oncol.
2017;39(6):420-424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28267088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao VK, Webster S, Dalm VASH, et al. . Effective “activated PI3Kδ syndrome”-targeted therapy with the PI3Kδ inhibitor leniolisib. Blood.
2017;130(21):2307-2316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5701526</ArticleId>
            <ArticleId IdType="pubmed">28972011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoegenauer K, Soldermann N, Zécri F, et al. . Discovery of CDZ173 (Leniolisib), representing a structurally novel class of PI3K delta-selective inhibitors. ACS Med Chem Lett.
2017;8(9):975-980.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5601375</ArticleId>
            <ArticleId IdType="pubmed">28947947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lanz AL, Riester M, Peters P, et al. . Abatacept for treatment-refractory pediatric CTLA4-haploinsufficiency. Clin Immunol.
2021;229:108779.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34116213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S, Moon JS, Lee CR, et al. . Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J Allergy Clin Immunol.
2016;137(1):327-330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26478010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiykim A, Ogulur I, Dursun E, et al. . Abatacept as a long-term targeted therapy for LRBA deficiency. J Allergy Clin Immunol Pract.
2019;7(8):2790-2800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6842687</ArticleId>
            <ArticleId IdType="pubmed">31238161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinacht KG, Charbonnier LM, Alroqi F, et al. . Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol.
2017;139(5):1629-1640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5482293</ArticleId>
            <ArticleId IdType="pubmed">28139313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bloomfield M, Kanderová V, Paračková Z, et al. . Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-function mutation. J Clin Immunol.
2018;38(5):589-601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29934865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forbes LR, Vogel TP, Cooper MA, et al. . Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol.
2018;142(5):1665-1669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6322659</ArticleId>
            <ArticleId IdType="pubmed">30092289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fahey LM, Wilson EB, Elsaesser H, Fistonich CD, McGavern DB, Brooks DG. Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. J Exp Med.
2011;208(5):987-999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3092345</ArticleId>
            <ArticleId IdType="pubmed">21536743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khosravi-Maharlooei M, Obradovic A, Misra A, et al. . Crossreactive public TCR sequences undergo positive selection in the human thymic repertoire. J Clin Invest.
2019;129(6):2446-2462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6546456</ArticleId>
            <ArticleId IdType="pubmed">30920391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madi A, Shifrut E, Reich-Zeliger S, et al. . T-cell receptor repertoires share a restricted set of public and abundant CDR3 sequences that are associated with self-related immunity. Genome Res.
2014;24(10):1603-1612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4199372</ArticleId>
            <ArticleId IdType="pubmed">25024161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madi A, Poran A, Shifrut E, et al. . T cell receptor repertoires of mice and humans are clustered in similarity networks around conserved public CDR3 sequences. eLife.
2017;6:6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5553937</ArticleId>
            <ArticleId IdType="pubmed">28731407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han JH, Suh CH, Jung JY, et al. . Elevated circulating levels of the interferon-γ-induced chemokines are associated with disease activity and cutaneous manifestations in adult-onset Still’s disease. Sci Rep.
2017;7(1):46652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5402387</ArticleId>
            <ArticleId IdType="pubmed">28436448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol.
2011;89(2):207-215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3863330</ArticleId>
            <ArticleId IdType="pubmed">21221121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Locatelli F, Jordan MB, Allen C, et al. . Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med.
2020;382(19):1811-1822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32374962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol.
2013;4:289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3792554</ArticleId>
            <ArticleId IdType="pubmed">24115947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young HA, Klinman DM, Reynolds DA, et al. . Bone marrow and thymus expression of interferon-gamma results in severe B-cell lineage reduction, T-cell lineage alterations, and hematopoietic progenitor deficiencies. Blood.
1997;89(2):583-595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9002962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Bruin AM, Voermans C, Nolte MA. Impact of interferon-γ on hematopoiesis. Blood.
2014;124(16):2479-2486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25185711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chinen T, Kannan AK, Levine AG, et al. . An essential role for the IL-2 receptor in Treg cell function. Nat Immunol.
2016;17(11):1322-1333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5071159</ArticleId>
            <ArticleId IdType="pubmed">27595233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol.
2005;174(11):6571-6576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15905493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malphettes M, Gérard L, Carmagnat M, et al. ; DEFI Study Group . Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect. Clin Infect Dis.
2009;49(9):1329-1338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19807277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo B, Zhang K, Lu W, et al. . Autoimmune disease. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science.
2015;349(6246):436-440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26206937</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
